SAN FRANCISCO — Adults with congenital adrenal hyperplasia treated with an oral nonsteroidal drug saw continued disease control with reduced daily glucocorticoid doses and other cardiometabolic improvements at 1 year, data show.In a series of analyses from the pivotal phase 3 CAHtalyst trial presented at ENDO 2025, researchers reported that participants with congenital adrenal hyperplasia
Researchers, including Ania M. Jastreboff, MD, PhD, detailed the results of a phase 2 study of maridebart cafraglutide for inducing weight loss in adults living…
Take action to help us support endocrinology research, care, professionals, and patients! We rely on you to advocate for our priorities.
Patients with COPD and type 2 diabetes had a reduced risk for COPD hospitalization, noninvasive positive-pressure ventilation and all-cause mortality if they used an SGLT-2…
Orthopedic surgeons are vital to the health care system, helping patients regain mobility and improve their quality of life.Joint replacement surgery ranks among the top…
In this episode, host Shikha Jain, MD, speaks with Elisabeth Potter, MD, about physicians pushing back against insurance companies, bringing physicians back into positions of…
The American College of Rheumatology is “disappointed” in the reductions to Medicaid funding included in the newly signed One Big Beautiful Bill Act, according to…
The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.
Thyroid cancer burden attributable to high BMI was increasing between 1990 and 2021 in the US, especially among men and older adults.
